UNSPSC 51273901: Benzocaine/calamine/zinc oxide

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE700. This VA Drug Class (DE700) classifies this compound as belonging to the group LOCAL ANESTHETICS, TOPICAL.

UNSPSC 51273901 Benzocaine/calamine/zinc oxide is a Commodity code, but recent state and local procurement activity under this code shows minimal alignment with the code's nominal scope—the posted opportunities involve naloxone, therapeutic pharmacy direct-to-manufacturer prescriptions, and generic multi-source pharmaceuticals and OTC products, none of which match the topical analgesic products the code describes. State and local governments do purchase OTC and pharmaceutical products broadly, including creams, ointments, and systemic medications for health and human services programs, but the three recent opportunities on file do not reflect procurement of benzocaine, calamine, or zinc oxide specifically. Issuing bodies range from county health departments (Seminole County, Florida) to state health agencies (Texas Health and Human Services Commission) to cooperative purchasing alliances serving multiple states (Minnesota Multistate Cooperative Purchasing Alliance, covering Minnesota, Oregon, and other participating jurisdictions). The cooperative purchasing vehicle appears active in this space, suggesting that state and local entities increasingly aggregate pharmaceutical and OTC procurement through multi-state agreements rather than individual solicitations.

Recent activity spans Florida, Texas, and the upper Midwest, with the most visible current opportunity being the Minnesota Multistate Cooperative Purchasing Alliance RFP for generic multi-source pharmaceuticals and OTC products, due March 26, 2026, which will supply authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co.) with awards effective July 1, 2026. Seminole County, Florida issued IFB60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023 (note: date discrepancy in source). The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for direct-to-manufacturer prescription programs. Given the mismatch between the code's stated scope and the opportunities posted, this code warrants watching for future activity; current pursuit is not recommended unless your firm specifically manufactures or distributes benzocaine, calamine, or zinc oxide formulations and can demonstrate recent wins under this or related topical-product codes.